|
Quotes & Info
|
| MTXX > SEC Filings for MTXX > Form 8-K on 10-Sep-2009 | All Recent SEC Filings |
10-Sep-2009
Change in Directors or Principal Officers
(e) As previously disclosed, on May 7, 2009, the Compensation Committee of
the Board of Directors of Matrixx Initiatives, Inc. (the "Company") approved the
fiscal year 2010 compensation plan (the "2010 Plan") for its executive officers,
which included retention and incentive components, payable in cash and
restricted stock. See the Company's Report on Form 8-K filed with the Securities
and Exchange Commission (the "SEC") on May 13, 2009 for additional information
regarding the 2010 Plan.
In light of recent developments associated with the Food and Drug
Administration's June 16, 2009 warning letter (the "Warning Letter") and the
Company's voluntary withdrawal of Zicam Cold Remedy Swabs and Zicam Cold Remedy
Nasal Gel products (see the Company's Reports on Form 8-K filed with the SEC on
June 16, 17, 19 and 23, July 2 and September 2, 2009), the Compensation
Committee determined that the 2010 Plan no longer functions as an effective
retention or incentive program. As a result, on September 3, 2009 the
Compensation Committee terminated the 2010 Plan and approved a new 2010 Plan
(the "New 2010 Plan") for the Company's executive officers, including the
following "named executive officers" included in the Company's proxy statement
relating to its August 26, 2009 annual meeting of shareholders (the "Named
Executive Officers"): William J. Hemelt; Samuel C. Cowley; Timothy L. Clarot;
and James Marini.
Like the 2010 Plan, the New 2010 Plan includes retention and incentive
components and the award opportunities under each Plan are of equal value;
however, awards under the New 2010 Plan will be payable solely in cash (versus
cash and restricted stock under the 2010 Plan). Each component of the New 2010
Plan is described below.
Retention Component. The award potential for each Named Executive Officer
under the retention component of the New 2010 Plan is 100% of such officer's
base salary as of September 2, 2009. Pursuant to an Executive Retention
Agreement between the Company and each Named Executive Officer, to be entered
into in September 2009, the Company will contribute an amount equal to 100% of
each Named Executive Officer's base salary into an employee grantor trust. The
amount in each Named Executive Officer's trust account will be paid from the
trust to such officer on April 1, 2010 if the officer remains employed by the
Company through such date. If a Named Executive Officer voluntarily terminates
his employment with the Company prior to April 1, 2010 without "good reason" (as
defined) or if the Company terminates the Named Executive Officer's employment
for "cause" (as defined), the retention award will be forfeited. If the Named
Executive Officer's employment with the Company is terminated prior to April 1,
2010 for any other reason, the retention award will be paid to the officer (or
his beneficiary) as of the date of termination of employment with the Company.
Incentive Component. The incentive component of the New 2010 Plan is based on
the Company's achievement of specified revenue levels. If the Company achieves a
specified target revenue level (the "First Target Revenue Level"), each Named
Executive Officer will receive the following cash incentive payment (expressed
as a percentage of the officer's base salary as of September 2, 2009):
Mr. Hemelt - (50%); Mr. Cowley - (40%); Mr. Clarot - (30%); and Mr. Marini -
(30%). If the Company achieves a revenue level between the First Target Revenue
Level and another, higher specified target revenue level (the "Second Target
Revenue Level"), the Named Executive Officers will receive no additional
incentive payments. If the Company exceeds the Second Target Revenue Level, then
the incentive award expressed as a percentage of each Named Executive Officer's
base salary will increase proportionately up to a maximum of 100% for
Mr. Hemelt, 80% for Mr. Cowley and 60% for each of Mr. Clarot and Mr. Marini.
|
|